Skip to content
Subscriber Only

J&J, Actelion Said to Reach Tentative Agreement on Price

  • Discussions now said to focus on valuing separated R&D unit
  • Companies could reach a final deal as soon as this month
Updated on

Johnson & Johnson has tentatively agreed with Actelion Ltd. on a price to acquire the Swiss biotechnology company, people with knowledge of the matter said, and talks are now focused on valuing what would be a new unit that would house the research and development assets.

Under the terms being discussed, Actelion’s R&D would be spun off into a new company and its shareholders would be able to keep some stock in that business, said the people, who asked not to be identified because the information is private. What exactly would be separated into that unit, and how much ownership Actelion investors would be able to keep, are the points under discussion, the people said.